AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker ...
AstraZeneca AZN announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rival Boehringer Ingelheim ...
March 18 (Reuters) - Drugmaker AstraZeneca (AZN.L), opens new tab said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from June, ...
(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...
President Biden on Wednesday will tout Democrats’ efforts to lower the cost of inhalers after drugmakers announced plans to cap prices. The president, alongside Sen. Bernie Sanders (I-Vt.
AstraZeneca (NASDAQ:AZN) plans to cap out-of-pocket costs for its inhaler medications at $35 per month following Congressional criticism of the company's pricing of the products in the US.
(Reuters) -Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States from June, following a similar move by ...